Health Canada Approves MYQORZO, Fifth Regulatory Win in Under a Year
CYTK sits 15% above its 52-week low of $54.3.
Summary
Health Canada granted a Notice of Compliance for MYQORZO (aficamten) in symptomatic obstructive HCM, NYHA class II-III adults. It is the fifth regulatory approval for the drug in less than a year, following the FDA in December 2025, China's NMPA, the European Commission, and the UK MHRA earlier in 2026. Canada is a smaller revenue market than the US or EU, so the near-term commercial impact is modest, but it reinforces the global rollout story that has driven the stock since launch. The approval rests on SEQUOIA-HCM Phase 3 data showing a 1.74 mL/kg/min placebo-adjusted improvement in peak VO2. Next item on the calendar is the planned Q4 2026 supplemental NDA submission for aficamten in non-obstructive HCM, which would roughly double the addressable population if approved.
At the time of this announcement, CYTK was trading at $62.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6B. The 52-week trading range was $54.30 to $88.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.